Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Treatment Reviews

• Publication date

  2016-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ctrv.2016.02.002PMID 26907461
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.

  2016cited by this paper
• Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

  2016cited by this paper
• Global cancer statistics, 2012

  2015cited by this paper
• Complexity of cancer protease biology: Cathepsin K expression and function in cancer progression.

  2015cited by this paper
• Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.

  2015cited by this paper
• Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).

  2015cited by this paper
• Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).

  2015cited by this paper
• Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme

  2015cited by this paper
• Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.

  2015cited by this paper
• Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment

  2015cited by this paper
• Final quality of life and safety data for patients with metastatic castration‐resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)

  2015cited by this paper
• Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

  2015cited by this paper
• Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.

  2015cited by this paper
• Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).

  2015influential reference
• Metastatic castration-resistant prostate cancer: time for innovation.

  2015cited by this paper
• Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

  2014cited by this paper
• Enzalutamide in metastatic prostate cancer before chemotherapy.

  2014cited by this paper
• Burden of skeletal-related events in prostate cancer: unmet need in pain improvement

  2014cited by this paper
• Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.

  2014cited by this paper
• Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

  2014cited by this paper
• A multi-targeted approach to treating bone metastases

  2014cited by this paper
• Health Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational Study

  2014cited by this paper
• Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

  2014cited by this paper
• Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.

  2014cited by this paper
• Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

  2013cited by this paper
• Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

  2013cited by this paper
• Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).

  2013cited by this paper
• Alpha emitter radium-223 and survival in metastatic prostate cancer.

  2013cited by this paper
• Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.

  2013cited by this paper
• Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study

  2013cited by this paper
• Targeting bone physiology for the treatment of metastatic prostate cancer.

  2013cited by this paper
• Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.

  2013cited by this paper
• Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

  2013cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

  2013cited by this paper
• Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

  2013cited by this paper
• Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.

  2013cited by this paper
• Re: Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• The prostate cancer bone marrow niche: more than just 'fertile soil'.

  2012influential reference
• Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases

  2012cited by this paper
• Prostate cancer and parasitism of the bone hematopoietic stem cell niche.

  2012cited by this paper
• Dasatinib combined with docetaxel for castration‐resistant prostate cancer

  2012cited by this paper
• Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

  2012cited by this paper
• Commentary on "Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone

  2012cited by this paper
• Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.

  2012cited by this paper
• Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

  2012cited by this paper
• Cancer to bone: a fatal attraction

  2011influential reference
• Abiraterone acetate

  2011cited by this paper
• Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Abiraterone Acetate

  2011cited by this paper
• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

  2011influential reference
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.

  2010cited by this paper
• The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.

  2010cited by this paper
• Cabazitaxel, a new taxane with favorable properties.

  2010cited by this paper
• Examining the metastatic niche: targeting the microenvironment.

  2010influential reference
• Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

  2009cited by this paper
• Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease

  2009cited by this paper
• Future therapeutic targets in osteoporosis

  2009cited by this paper
• Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

  2009cited by this paper
• Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

  2009cited by this paper
• Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

  2009cited by this paper
• Src as a therapeutic target in men with prostate cancer and bone metastases

  2009cited by this paper
• The cost of treating skeletal-related events in patients with prostate cancer.

  2008cited by this paper
• Src and focal adhesion kinase as therapeutic targets in cancer.

  2008cited by this paper
• Mechanisms of bone metastasis in prostate cancer: clinical implications.

  2008influential reference
• Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer

  2008cited by this paper
• Results from a phase 1/2 study of volociximab in combination with liposomal doxorubicin in relapsed advanced epithelial ovarian and primary peritoneal carcinoma

  2008cited by this paper
• Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study

  2008cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

  2008cited by this paper
• Impact of skeletal complications on patients’ quality of life, mobility, and functional independence

  2008cited by this paper
• Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

  2008cited by this paper
• Impact of skeletal complications on patients’ quality of life, mobility, and functional independence

  2008cited by this paper
• Emerging roles of cysteine cathepsins in disease and their potential as drug targets.

  2007cited by this paper
• Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.

  2007cited by this paper
• Expression and activation of αvβ3 integrins by SDF‐1/CXC12 increases the aggressiveness of prostate cancer cells

  2007cited by this paper
• Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873).

  2007cited by this paper
• Pathologic fractures correlate with reduced survival in patients with malignant bone disease

  2007cited by this paper
• Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells.

  2007cited by this paper
• High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?

  2006cited by this paper
• Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer

  2006cited by this paper
• High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?

  2006cited by this paper
• Evaluation of functional outcome and local control after radiotherapy for metastatic spinal cord compression in patients with prostate cancer.

  2006cited by this paper
• Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.

  2006cited by this paper
• Pre- and post-treatment daily life function in patients with hormone resistant prostate carcinoma treated with radiotherapy for spinal cord compression.

  2005cited by this paper
• Endothelin receptor antagonists

  2005cited by this paper
• The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer.

  2005influential reference
• Bone-seeking radionuclides for therapy.

  2005cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

  2004cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004influential reference
• A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

  2003cited by this paper
• Endothelin inhibition: novel therapy for prostate cancer.

  2003cited by this paper
• Expression of CXCR4 and CXCL12 (SDF‐1) in human prostate cancers (PCa) in vivo

  2003cited by this paper
• Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice.

  2003cited by this paper
• Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.

  2003cited by this paper

• Post-operative survival and use of systemic therapy in metastatic long-bone disease: 12 years of institutional experience.

  2026cites this paper
• Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art

  2025cites this paper
• Clinical profiles and predictors of symptomatic skeletal events in patients with metastatic castration-resistant prostate cancer receiving denosumab

  2025cites this paper
• Prognostic value of whole-body diffusion-weighted imaging with background body signal suppression in CRPC patients undergoing Ra-223 therapy: an exploratory analysis

  2025cites this paper
• Lutetium-177 Theranostics and Dosimetry for Neuroendocrine Neoplasms and Prostate Cancer.

  2025cites this paper
• Assessing the Impact of Agents with Antiviral Activities on Transmembrane Ionic Currents: Exploring Possible Unintended Actions

  2024cites this paper
• Redefining Treatment Paradigms in Metastatic Castration-resistant Prostate Cancer: A Comprehensive Analysis of Cabozantinib and Atezolizumab Based on the CONTACT-02 Study Results

  2024cites this paper
• Crosstalk between bone metastatic cancer cells and sensory nerves in bone metastatic progression

  2024cites this paper
• Role of osteoclast inhibitors in prostate cancer bone metastasis; a narrative review

  2024cites this paper
• Identification of Molecular Markers Associated with Prostate Cancer Subtypes: An Integrative Bioinformatics Approach

  2024cites this paper
• Comprehensive Analysis of m5C Methylation Regulatory Genes and Tumor Microenvironment in Prostate Cancer

  2022cites this paper
• Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool

  2022influential citation
• Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review

  2022cites this paper
• Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis

  2022cites this paper
• Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”

  2021cites this paper
• Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands.

  2021cites this paper
• Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases

  2021cites this paper
• Pathophysiology of Bone Loss in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy and Lifestyle Modifications for the Management of Bone Health: A Comprehensive Review

  2020cites this paper
• Cabozantinib Reverses Renal Cell Carcinoma–mediated Osteoblast Inhibition in Three-dimensional Coculture In Vitro and Reduces Bone Osteolysis In Vivo

  2020cites this paper
• Osteoblasts derived from mouse mandible enhance tumor growth of prostate cancer more than osteoblasts derived from long bone

  2020cites this paper
• Spine and Non-spine Bone Metastases - Current Controversies and Future Direction.

  2020cites this paper
• Role of the CXCR4/ALK5/Smad3 Signaling Pathway in Cancer-Induced Bone Pain

  2020cites this paper
• Implication of Prophetic Variables and Their Impulsive Interplay in CA Prostate Patients Experiencing Osteo-Metastasis.

  2020cites this paper
• Switching Homes: How Cancer Moves to Bone

  2020cites this paper
• Bone Health in Men with Prostate Cancer: Review Article

  2019cites this paper
• Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma

  2019cites this paper
• Clinical benefit of early treatment with bone‐modifying agents for preventing skeletal‐related events in patients with genitourinary cancer with bone metastasis: A multi‐institutional retrospective study

  2019cites this paper
• Predictors of skeletal‐related events and mortality in men with metastatic, castration‐resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

  2019cites this paper
• Genomic Mutation as A Potential Driver of The Development of Bone-Related Cancers

  2019cites this paper
• Prognostic significance of the presence of intraductal carcinoma of the prostate and bone metastasis in needle biopsy for prostate carcinoma patients with Grade Group 5.

  2019cites this paper
• Economic Evaluations of Cabazitaxel for Treatment of Post-docetaxel Metastatic Castration-resistant Prostate Cancer: Evidence from a Systematic Review

  2019cites this paper
• Novel Approaches of Treatment with Radium-223 Targeted Therapy

  2018cites this paper
• Skeletal Complications in Patients with CRPC

  2018cites this paper
• Metastatic prostate cancer remains incurable, why?

  2018cites this paper
• The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer

  2018cites this paper
• Revisiting the role of bone‐modifying agents in the management of metastatic prostate cancer

  2018cites this paper
• Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review

  2018cites this paper
• Living and dying with prostate cancer Population-based register studies

  2018cites this paper
• Alloreactive cytotoxic T lymphocyte immunotherapy treatment of a patient with metastatic prostate cancer

  2018cites this paper
• The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.

  2018influential citation
• Targeted alpha therapy using Radium-223: From physics to biological effects.

  2018cites this paper
• Inhibition of Histone Deacetylases Attenuates Morphine Tolerance and Restores MOR Expression in the DRG of BCP Rats

  2018cites this paper
• Role of the Bone Microenvironment in the Development of Painful Complications of Skeletal Metastases

  2018cites this paper
• An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer.

  2018cites this paper
• Bone-Targeted Treatment in CRPC Management

  2018cites this paper
• Bone Metastases in Prostate Cancer

  2018cites this paper
• Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment.

  2017cites this paper
• بیسفسفوناتها در درمان سرطان پیشرفته پروستات

  2017cites this paper
• Cellular determinants and microenvironmental regulation of prostate cancer metastasis.

  2017cites this paper
• Bisphosphonates for advanced prostate cancer.

  2017cites this paper
• Overcoming immunosuppression in bone metastases.

  2017cites this paper
• Biochemical Changes in the Niche Following Tumor Cell Invasion

  2017cites this paper
• The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience

  2017cites this paper
• Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models

  2017cites this paper
• The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.

  2017cites this paper
• Prostate Spinal Metastasis: An Update and Review.

  2017influential citation
• Surgery: Treatment of Oligometastatic Disease

  2017cites this paper
• Modern treatment of metastatic prostate cancer.

  2017cites this paper
• Radium-223 in a Community Setting for Castration Resistant Prostate Cancer

  2017cites this paper
• Biomaterial-Mediated Drug Delivery in Primary and Metastatic Cancers of the Bone

  2017cites this paper
• Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy

  2017cites this paper
• Targeting MCT4 for treatment of advanced prostate cancers : inhibiting cell proliferation and enhancing anticancer immunity through suppressing lactic acid secretion and elevated glycolysis

  2017influential citation
• Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer

  2016cites this paper
• Therapeutic management of bone metastasis in prostate cancer: an update

  2016cites this paper
• Synthesis of Psoralidin derivatives and their anticancer activity: First synthesis of Lespeflorin I1.

  2016cites this paper
• Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?

  2016cites this paper
• Targeting multidrug-resistant ovarian cancer through estrogen receptor α dependent ATP depletion caused by hyperactivation of the unfolded protein response

  2014cites this paper
• Concepts and Surgical Treatment of Metastatic Bone Disease

  2013cites this paper